logo
Share SHARE
FONT-SIZE Plus   Neg

Biogen Submits BLA For First Long-Lasting Factor VIII Therapy For Hemophilia A

Biogen Idec (BIIB) reported submitting a Biologics License Application or BLA to the U.S. Food and Drug Administration or FDA for the marketing approval of recombinant factor VIII Fc fusion protein or rFVIIIFc to treat hemophilia A. Recombinant FVIIIFc is the first hemophilia A product candidate in a new class of long-lasting clotting factor therapies being developed with the goal of reducing the burden of treatment for this condition.

If approved, rFVIIIFc would be the first major advance in hemophilia A treatment in more than two decades, according to the company. The regulatory submission was based on results from A-LONG, the largest registrational phase 3 trial in hemophilia A to date.

Biogen Idec added, "In our phase 3 study, patients treated with rFVIIIFc were able to inject rFVIIIFc once-weekly to twice-weekly, which creates the potential for those currently on prophylactic treatment to reduce injections by 50 to 100 per year. Moreover, patients currently treating bleeding episodes could potentially dose prophylactically once per week and maintain significant protection from bleeding with about the same total number of injections each year they use to treat bleeding episodes today."

On March 4, 2013 Biogen Idec announced the FDA accepted for review the company's BLA for its factor IX candidate, rFIXFc, for use in patients with hemophilia B.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
General Motors' Chevrolet, the first automotive brand to add 4G LTE connectivity across its entire vehicle portfolio, has now slashed its OnStar 4G LTE data plan pricing by up to 50 percent ahead of the upcoming 2016 Independence Day, the company said in a statement. Shares of Tractor Supply Co. (TSCO) slipped over 7 percent in the extended hours after the company issued a weak second-quarter guidance and lowered its annual outlook, due to weak sales of its seasonal products. For the second quarter, the company now expects earnings of $1.15 to $1.16 per share... Hard-disk driver maker Seagate Technology plc (STX) late Wednesday said it was cutting 1,600 jobs or about 3% of its global workforce to curb expenses. The company expects to save about $100 million a year, having a favorable impact on cost of revenue and operating expenses by about $48 million and...
comments powered by Disqus
Follow RTT